Solute carrier family 22 member 3 (SLC22A3) showed up-regulation in pancreatic cancer when compared with non-neoplastic pancreatic tissues, and patients with high expression of SLC22A3 may benefit from nucleoside analogs71. This evidence concerns the gene SLC22A3 and familial pancreatic carcinoma.